.jpg?#)
Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s
Novo Nordisk gets global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisk’s Wegovy. The post Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s appeared first on MedCity News.
Novo Nordisk gets global rights to Lexicon Pharmaceuticals’ LX9851, an oral small molecule with a first-in-class approach to sparking weight loss. The licensing agreement comes months after Lexicon reported encouraging preclinical data from tests of LX9851 in combination with semaglutide, the main ingredient in Novo Nordisk’s Wegovy.
The post Novo Nordisk Lands Lexicon Pharma Obesity Drug With Potential to Pair With GLP-1s appeared first on MedCity News.
